The Cell and Gene Therapy stream highlights cutting-edge solutions for scaling, controlling, and expanding access to advanced therapies. The Cell Therapy track explores strategies to cut costs, enhance quality, and streamline manufacturing. Topics include lessons from approved products, centralized and Point-of-Care models, automation, digital twins, and AI/ML integration. The program also examines in vivo CAR T as a disruptive manufacturing paradigm with distinct CMC and regulatory considerations. The Gene Therapy track focuses on advancing viral and non-viral vector manufacturing, process intensification, and control strategies for safer, more scalable therapies. Sessions cover novel capsids, scaling next-generation vectors, mRNA-LNP platforms, and gene editing, showcasing how innovation in manufacturing and CMC is driving next-generation therapies toward broader patient access.

Conferences Include: